Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Akeso, Inc. ( (HK:9926) ).
Akeso, Inc. announced that all approved indications of its five marketed innovative drugs have been included in China’s 2025 National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion is expected to enhance the company’s market presence and accessibility of its treatments, potentially benefiting patients with various conditions such as cancer, hypercholesterolemia, and psoriasis.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
More about Akeso, Inc.
Akeso, Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and marketing of innovative drugs. The company is committed to providing first-in-class and best-in-class treatment therapies, enhancing their accessibility and affordability across major therapeutic areas.
Average Trading Volume: 9,618,821
Technical Sentiment Signal: Buy
Current Market Cap: HK$114.3B
For a thorough assessment of 9926 stock, go to TipRanks’ Stock Analysis page.